NeuroSense Therapeutics Ltd. Warrant closed at $0.04 on Sep 25, down 55.44%, within 2.3% of its lowest close since Dec 9. Volume of 1.1K shares was 0.48× its 20-day average (below normal).
Split-adjusted performance: -42.7% over one month, -80.0% over six months.
Short interest was 1.8K shares at the Sep 15 settlement, down 19.8% from the prior report (4.8 days to cover).
No recent articles focused on NeuroSense Therapeutics Ltd. Warrant.
Quick answers
What does NeuroSense Therapeutics Ltd. Warrant do?
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others.
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
